fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-04-12 Almac Group (UK)
MRC (UK)
Merck KGaA (Germany)
assessment of markers of response to cetuximab therapy / metastatic colorectal cancer R&D
other
See details
2010-04-12 PregLem (Switzerland)
HRA Pharma (France)
ulipristal acetate / benign gynaecological disorders commercialization/ distribution
development
marketing/ promotion
See details
2010-04-12 Naval Medical Research Center (NMRC - USA)
Sanofi Pasteur (France)
vaccine against enterotoxigenic Escherichia coli (ETEC) / travelers' diarrhea R&D
licensing
See details
2010-04-08 Swedish Orphan Biovitrum (Sweden)
LFB (France)
Willfact® (plasma derived human von Willebrand factor (vWF) concentrate) commercialization/ distribution
See details
2010-04-08 CureDM (USA)
Sanofi-Aventis (France)
Pancreate®(proisletide acetate)
This first-in-class human peptide (HIP-2B) sequence of a naturally occurring human protein stimulates the formation of functional insulin producing neo-islets from pancreatic progenitor cells. / type 1 and type 2 diabetes.
licensing
manufacturing
commercialization/ distribution
development
marketing/ promotion
See details
2010-04-08 Galapagos (Belgium)
Bausch & Lomb (USA)
/ ophthalmic diseases

licensing
See details
2010-04-08 Debiopharm (Switzerland)
Biocartis (Switzerland)
companion diagnostics / oncology, infectious diseases R&D
other
See details
2010-04-07 Domainex (UK)
The Institute of Cancer Research (UK)
lead optimisation services to find a new treatment for breast cancer.
This new treatment is based on drug-like compounds that inhibit an enzyme from the PARP superfamily, whose expression leads to the survival of breast cancer cells. / breast cancer
R&D
other
See details
2010-04-06 BioAlliance Pharma (France)
Therabel Group (France)
Loramyc® and Setofilm® /

commercialization/ distribution
other
See details
2010-04-06 Crucell (The Netherlands)
GSK Biologicals (Belgium - UK)
malaria vaccine Ad35-CS / malaria R&D
development
See details
2010-03-31 Isis Pharmaceuticals (USA)
GSK (UK)
antisense therapies / rare diseases, infectious diseases R&D
licensing
commercialization/ distribution
development
See details
2010-03-31 Source BioScience (UK)
AstraZeneca (UK)
companion diagnostic genetic testing service / lung cancer other
See details
2010-03-30 Dicerna Pharmaceuticals (USA)
Ipsen (France)
RNAi therapeutics (conjugates of DsiRNA molecules and peptide targeting vectors)
DsiRNA (Dicer Substrate RNAi) are based on a critical enzyme involved in the RNAi gene silencing cascade, Dicer. This enzyme acts earlier in the pathway, preparing double-stranded RNA for processing. Dicer then hands off these small RNA molecules to the mature gene silencing complex (RISC). Dicerna’s molecules are 25 or more base pairs in length and take advantage of this natural and early entry point.
/ oncology and endocrinology
R&D
development
See details
2010-03-26 Actelion (Switzerland)
Invida (Singapore)
Tracleer® (bosentan) / pulmonary arterial hypertension (PAH) commercialization/ distribution
See details
2010-03-25 Cellectis (France)
Boehringer Ingelheim (Germany)
homologous recombination patents
licensing
See details
[<<]      «      3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11   |   12   |   13      »      [65]